RecruitingNot ApplicableNCT05957445

pBFS-guided Multi-target cTBS for Aphasia After Stroke

Personalized Brain Functional Sector-guided Multi-target Continuous Theta Burst Stimulation Therapy for Aphasia After Stroke: a RCT


Sponsor

Changping Laboratory

Enrollment

60 participants

Start Date

Aug 23, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

In this study, a randomized, double-blind, parallel-controlled trial was employed to evaluate the effectiveness and safety of personalized brain functional sectors (pBFS) technology-guided continuous theta burst stimulation (cTBS) on the inferior frontal gyrus (IFG) combined with the superior temporal gyrus (STG) and the superior frontal gyrus (SFG) for language function recovery in post-stroke aphasic patients.


Eligibility

Min Age: 35 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called active continuous Theta Burst Stimulation and a medical device called sham continuous Theta Burst Stimulation for people with aphasia and stroke. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 35 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEactive continuous Theta Burst Stimulation

Each patient will receive a series of stimulation sequences, including a 600-pulse cTBS targeting at the right IFG, followed by a 600-pulse cTBS targeting at the right STG, and subsequently a 600-pulse cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.

DEVICEsham continuous Theta Burst Stimulation

Each patient will receive a series of stimulation sequences,including a 600-pulse sham cTBS targeting at the right IFG, followed by a 600-pulse sham cTBS targeting at the right STG, and subsequently a 600-pulse sham cTBS targeting at the right SFG. This sequence will be repeated once more (a total of 3600 pulses daily). Each patient will receive a 3-week treatment period, consisting of 5 consecutive workdays each week.


Locations(3)

Affiliated Hospital of Hebei University

Baoding, Hebei, China

Affiliated Hospital of Chengde Medical University

Chengde, Hebei, China

Hebei General Hospital

Shijiazhuang, Hebei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05957445


Related Trials